91ÖÆƬ³§

Published on Market Research Reports® Inc. ()

Home > Global Liposome Drug Delivery Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Global Liposome Drug Delivery Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Publication ID: 
PB503252438
Publication Date: 
March 31, 2025
Pages: 
100
Publisher: 
MRRPB5
Countries: 
Global [1]
USD 4,250.00

Please choose the suitable license type from above. More details are given under tab "Report License Types" below.

Healthcare [2]
Pharma & Healthcare [3]
Description: 

The global Liposome Drug Delivery market size was US$ 4742 million in 2024 and is forecast to a readjusted size of US$ 10890 million by 2031 with a CAGR of 12.8% during the forecast period 2025-2031.
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only. In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.
Global Liposome Drug Delivery key players include Gilead Sciences, Pacira, Sun Pharmaceutical, Johnson & Johnson, Luye Pharma, etc. Global top five manufacturers hold a share about 60%. North America is the largest market, with a share about 40%, followed by Europe and Asia-Pacific, both with a share about 30 percent. In terms of product, Liposomal Doxorubicin is the largest segment, with a share about 40%. And in terms of application, the largest application is Cancer & Tumor Therapy, followed by Fungal Infection Therapy, etc.
The global Liposome Drug Delivery market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Gilead Sciences
Pacira
Sun Pharmaceutical
Johnson & Johnson
Luye Pharma
Sigma-Tau
Ipsen (Onivyde)
CSPC
Teva Pharmaceutical
Novartis
Fudan-Zhangjiang
By Type: (Dominant Segment vs High-Margin Innovation)
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
By Application: (Core Demand Driver vs Emerging Opportunity)
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Gilead Sciences in Europe)
- Emerging Product Trends: Liposomal Doxorubicin adoption vs. Liposomal Amphoteracin B premiumization
- Demand-Side Dynamics: Fungal Infection Therapy growth in China vs. Cancer & Tumor Therapy potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
India
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Liposome Drug Delivery market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Liposomal Amphoteracin B in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Cancer & Tumor Therapy in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Liposomal Doxorubicin dominance in Europe vs. Liposomal Amphoteracin B demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents: 

1 Market Overview
1.1 Liposome Drug Delivery Product Scope
1.2 Liposome Drug Delivery by Type
1.2.1 Global Liposome Drug Delivery Sales by Type (2020 & 2024 & 2031)
1.2.2 Liposomal Doxorubicin
1.2.3 Liposomal Amphoteracin B
1.2.4 Liposomal Paclitaxel
1.2.5 Others
1.3 Liposome Drug Delivery by Application
1.3.1 Global Liposome Drug Delivery Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Fungal Infection Therapy
1.3.3 Cancer & Tumor Therapy
1.3.4 Others
1.4 Global Liposome Drug Delivery Market Estimates and Forecasts (2020-2031)
1.4.1 Global Liposome Drug Delivery Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Liposome Drug Delivery Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Liposome Drug Delivery Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Liposome Drug Delivery Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Liposome Drug Delivery Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Liposome Drug Delivery Sales Market Share by Region (2020-2025)
2.2.2 Global Liposome Drug Delivery Revenue Market Share by Region (2020-2025)
2.3 Global Liposome Drug Delivery Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Liposome Drug Delivery Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Liposome Drug Delivery Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Liposome Drug Delivery Market Size and Prospective (2020-2031)
2.4.2 Europe Liposome Drug Delivery Market Size and Prospective (2020-2031)
2.4.3 China Liposome Drug Delivery Market Size and Prospective (2020-2031)
2.4.4 Japan Liposome Drug Delivery Market Size and Prospective (2020-2031)
2.4.5 India Liposome Drug Delivery Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Liposome Drug Delivery Historic Market Review by Type (2020-2025)
3.1.1 Global Liposome Drug Delivery Sales by Type (2020-2025)
3.1.2 Global Liposome Drug Delivery Revenue by Type (2020-2025)
3.1.3 Global Liposome Drug Delivery Price by Type (2020-2025)
3.2 Global Liposome Drug Delivery Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Liposome Drug Delivery Sales Forecast by Type (2026-2031)
3.2.2 Global Liposome Drug Delivery Revenue Forecast by Type (2026-2031)
3.2.3 Global Liposome Drug Delivery Price Forecast by Type (2026-2031)
3.3 Different Types Liposome Drug Delivery Representative Players
4 Global Market Size by Application
4.1 Global Liposome Drug Delivery Historic Market Review by Application (2020-2025)
4.1.1 Global Liposome Drug Delivery Sales by Application (2020-2025)
4.1.2 Global Liposome Drug Delivery Revenue by Application (2020-2025)
4.1.3 Global Liposome Drug Delivery Price by Application (2020-2025)
4.2 Global Liposome Drug Delivery Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Liposome Drug Delivery Sales Forecast by Application (2026-2031)
4.2.2 Global Liposome Drug Delivery Revenue Forecast by Application (2026-2031)
4.2.3 Global Liposome Drug Delivery Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Liposome Drug Delivery Application
5 Competition Landscape by Players
5.1 Global Liposome Drug Delivery Sales by Players (2020-2025)
5.2 Global Top Liposome Drug Delivery Players by Revenue (2020-2025)
5.3 Global Liposome Drug Delivery Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposome Drug Delivery as of 2024)
5.4 Global Liposome Drug Delivery Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Liposome Drug Delivery, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Liposome Drug Delivery, Product Type & Application
5.7 Global Key Manufacturers of Liposome Drug Delivery, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Liposome Drug Delivery Sales by Company
6.1.1.1 North America Liposome Drug Delivery Sales by Company (2020-2025)
6.1.1.2 North America Liposome Drug Delivery Revenue by Company (2020-2025)
6.1.2 North America Liposome Drug Delivery Sales Breakdown by Type (2020-2025)
6.1.3 North America Liposome Drug Delivery Sales Breakdown by Application (2020-2025)
6.1.4 North America Liposome Drug Delivery Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Liposome Drug Delivery Sales by Company
6.2.1.1 Europe Liposome Drug Delivery Sales by Company (2020-2025)
6.2.1.2 Europe Liposome Drug Delivery Revenue by Company (2020-2025)
6.2.2 Europe Liposome Drug Delivery Sales Breakdown by Type (2020-2025)
6.2.3 Europe Liposome Drug Delivery Sales Breakdown by Application (2020-2025)
6.2.4 Europe Liposome Drug Delivery Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Liposome Drug Delivery Sales by Company
6.3.1.1 China Liposome Drug Delivery Sales by Company (2020-2025)
6.3.1.2 China Liposome Drug Delivery Revenue by Company (2020-2025)
6.3.2 China Liposome Drug Delivery Sales Breakdown by Type (2020-2025)
6.3.3 China Liposome Drug Delivery Sales Breakdown by Application (2020-2025)
6.3.4 China Liposome Drug Delivery Major Customer
6.3.5 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Liposome Drug Delivery Sales by Company
6.4.1.1 Japan Liposome Drug Delivery Sales by Company (2020-2025)
6.4.1.2 Japan Liposome Drug Delivery Revenue by Company (2020-2025)
6.4.2 Japan Liposome Drug Delivery Sales Breakdown by Type (2020-2025)
6.4.3 Japan Liposome Drug Delivery Sales Breakdown by Application (2020-2025)
6.4.4 Japan Liposome Drug Delivery Major Customer
6.4.5 Japan Market Trend and Opportunities
6.5 India Market: Players, Segments, Downstream and Major Customers
6.5.1 India Liposome Drug Delivery Sales by Company
6.5.1.1 India Liposome Drug Delivery Sales by Company (2020-2025)
6.5.1.2 India Liposome Drug Delivery Revenue by Company (2020-2025)
6.5.2 India Liposome Drug Delivery Sales Breakdown by Type (2020-2025)
6.5.3 India Liposome Drug Delivery Sales Breakdown by Application (2020-2025)
6.5.4 India Liposome Drug Delivery Major Customer
6.5.5 India Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Gilead Sciences
7.1.1 Gilead Sciences Company Information
7.1.2 Gilead Sciences Business Overview
7.1.3 Gilead Sciences Liposome Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Gilead Sciences Liposome Drug Delivery Products Offered
7.1.5 Gilead Sciences Recent Development
7.2 Pacira
7.2.1 Pacira Company Information
7.2.2 Pacira Business Overview
7.2.3 Pacira Liposome Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
7.2.4 Pacira Liposome Drug Delivery Products Offered
7.2.5 Pacira Recent Development
7.3 Sun Pharmaceutical
7.3.1 Sun Pharmaceutical Company Information
7.3.2 Sun Pharmaceutical Business Overview
7.3.3 Sun Pharmaceutical Liposome Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Sun Pharmaceutical Liposome Drug Delivery Products Offered
7.3.5 Sun Pharmaceutical Recent Development
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Company Information
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Liposome Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
7.4.4 Johnson & Johnson Liposome Drug Delivery Products Offered
7.4.5 Johnson & Johnson Recent Development
7.5 Luye Pharma
7.5.1 Luye Pharma Company Information
7.5.2 Luye Pharma Business Overview
7.5.3 Luye Pharma Liposome Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Luye Pharma Liposome Drug Delivery Products Offered
7.5.5 Luye Pharma Recent Development
7.6 Sigma-Tau
7.6.1 Sigma-Tau Company Information
7.6.2 Sigma-Tau Business Overview
7.6.3 Sigma-Tau Liposome Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Sigma-Tau Liposome Drug Delivery Products Offered
7.6.5 Sigma-Tau Recent Development
7.7 Ipsen (Onivyde)
7.7.1 Ipsen (Onivyde) Company Information
7.7.2 Ipsen (Onivyde) Business Overview
7.7.3 Ipsen (Onivyde) Liposome Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Ipsen (Onivyde) Liposome Drug Delivery Products Offered
7.7.5 Ipsen (Onivyde) Recent Development
7.8 CSPC
7.8.1 CSPC Company Information
7.8.2 CSPC Business Overview
7.8.3 CSPC Liposome Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
7.8.4 CSPC Liposome Drug Delivery Products Offered
7.8.5 CSPC Recent Development
7.9 Teva Pharmaceutical
7.9.1 Teva Pharmaceutical Company Information
7.9.2 Teva Pharmaceutical Business Overview
7.9.3 Teva Pharmaceutical Liposome Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
7.9.4 Teva Pharmaceutical Liposome Drug Delivery Products Offered
7.9.5 Teva Pharmaceutical Recent Development
7.10 Novartis
7.10.1 Novartis Company Information
7.10.2 Novartis Business Overview
7.10.3 Novartis Liposome Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
7.10.4 Novartis Liposome Drug Delivery Products Offered
7.10.5 Novartis Recent Development
7.11 Fudan-Zhangjiang
7.11.1 Fudan-Zhangjiang Company Information
7.11.2 Fudan-Zhangjiang Business Overview
7.11.3 Fudan-Zhangjiang Liposome Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
7.11.4 Fudan-Zhangjiang Liposome Drug Delivery Products Offered
7.11.5 Fudan-Zhangjiang Recent Development
8 Liposome Drug Delivery Manufacturing Cost Analysis
8.1 Liposome Drug Delivery Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Liposome Drug Delivery
8.4 Liposome Drug Delivery Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Liposome Drug Delivery Distributors List
9.3 Liposome Drug Delivery Customers
10 Liposome Drug Delivery Market Dynamics
10.1 Liposome Drug Delivery Industry Trends
10.2 Liposome Drug Delivery Market Drivers
10.3 Liposome Drug Delivery Market Challenges
10.4 Liposome Drug Delivery Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer

Companies Mentioned: 

Gilead Sciences
Pacira
Sun Pharmaceutical
Johnson & Johnson
Luye Pharma
Sigma-Tau
Ipsen (Onivyde)
CSPC
Teva Pharmaceutical
Novartis
Fudan-Zhangjiang

License Types: 

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ìý

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ìý

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL:/mrrpb5/global-liposome-drug-delivery-sales-market-report-competitive-analysis-and-regional

Links
[1] /countries/global[2] /healthcare[3] /pharma-healthcare